A newly developed adenovirus-mediated transfer of a wild-type p53 gene increases sensitivity to cis-diamminedichloroplatinum (II) in p53-deleted ovarian cancer cells

European Journal of Cancer

Volumn 34, Issue 11, 1998, Pages 1802-1806

  Kanamori, Y ^a   Kigawa, J ^a   Minagawa, Y ^a   Irie, T ^a   Oishi, T ^a   Shimada, M ^a   Takahashi, M ^a   Nakamura, T ^a   Sato, K ^a   Terakawa, N ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

CDDP; Ovarian cancer; P53 gene transfer; Recombinant adenovirus

Indexed keywords

CISPLATIN; PROTEIN P53;

ADENOVIRUS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; FEMALE; GENE DELETION; GENE TRANSFER; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; VIRUS RECOMBINANT;

ADENOCARCINOMA; ADENOVIRUSES, HUMAN; ANTINEOPLASTIC AGENTS; APOPTOSIS; CISPLATIN; COMBINED MODALITY THERAPY; FEMALE; GENE TRANSFER TECHNIQUES; GENES, P53; HUMANS; MALE; OVARIAN NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0032190372     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00199-3     Document Type: Article

References (22)

1. 1. Maggie FM. Cisplatin update. Semin Oncol 1991, 8, 1-4.
2. 2. Kigawa J, Minagawa Y, Ishihara H, Kanamori Y, Terakawa N. Tumor DNA ploidy and prognosis of patients with serous cystadenocarcinoma of the ovary. Cancer 1993, 72, 804-808.
3. 3. Williams GT, Smith CA. Molecular regulation of apoptosis: genetic controls on cell death. Cell 1993, 74, 777-779.
4. 4. Kastan MB, Canman CE, Leonard CJ. p53 cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev 1995, 14, 3-15.
5. 5. Kellen JA. Molecular interrelationships in multidrug resistance. Anticancer Res 1994, 14, 433-435.
6. 6. Man S, Bani MR, Adachi D, et al. Retroviral insertional mutagenesis as a strategy for the identification of genes associated with cis-diamminedichloroplatinum(II) resistance. Cancer Res 1995, 55, 1139-1145.
7. 7. Righetti SC, Della TG, Pilotti S, et al. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 1996, 56, 689-693.
8. 8. Jonathan J, Herod O, Eliopoulos AG, et al. The prognostic significance of Bcl-2 and p53 expression in ovarian cancer. Cancer Res 1996, 56, 2178-2184.
9. 9. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 1991, 108, 193-199.
10. 10. Miyake S, Makimura M, Kanegae Y, et al. Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. Proc Natl Acad Sci USA 1996, 93, 1320-1324.
11. 11. Kanegae Y, Makimura Y, Saito I. A simple and efficient method for purification of infectious recombinant adenovirus. Jpn J Med Sci Biol 1994, 47, 157-166.
12. 12. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72, 248-254.
13. 13. Mosmann T. Rapid calorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65, 55-63.
14. 14. Finney DJ. Statistical logic in the monitoring of reactions to therapeutic drugs. Methods Inf Med 1971, 10, 237-245.
15. 15. Mujoo K, Maneval DC, Anderson SC, Gutterman JU. Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma. Oncogene 1996, 12, 1617-1623.
16. 16. Hamada K, Alemany R, Zhang WW, et al. Adenovirus-mediated transfer of a wild-type p53 gene and introduction of apoptosis in cervical cancer. Cancer Res 1996, 56, 3047-3054.
17. 17. Fukuchi K, Hearn MG, Deeb S, et al. Activity assays of nine heterogeneous promoters in neural and other cultured cells. In Vitro Cell Dev Biol Anim 1994, 30, 300-305.
18. 18. Polyak K, Waldman T, He TC, Kinzler KW, Volgelstein B. Genetic determinations of p53-induced apoptosis and growth arrest. Genes Dev 1996, 10, 1945-1952.
19. 19. Fritsche M, Haessler C, Brandner G. Induction of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. Oncogene 1993, 8, 307-318.
20. 20. Perego P, Giarola M, Righetti SC, et al. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 1996, 56, 556-562.
21. 21. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen SLB, Roth JA. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 1994, 54, 2287-2291.
22. 22. Nguyen DM, Spitz FR, Yen N, Cristiano RJ, Roth JA. Gene therapy for lung cancer: enhancement of tumor suppression by a combination of sequential systemic cisplatin and adenovirusmediated p53 gene transfer. J Thorac Cardiovasc Surg 1996, 112, 1372-1376.